Education
About Us
Working with TipRanks
Follow Us
Bicara Therapeutics Inc. (BCAX)
NASDAQ:BCAX
Total Valuation
Bicara Therapeutics Inc. has a market cap or net worth of $605.90M. The enterprise value is $182.60M.
Market Cap$605.90M
Enterprise Value$182.60M
Share Statistics
Bicara Therapeutics Inc. has 54,536,217 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding54,536,217
Owned by Insiders37.30%
Owned by Institutions0.28%
Financial Efficiency
Bicara Therapeutics Inc.’s return on equity (ROE) is -0.14 and return on invested capital (ROIC) is -16.77%.
Return on Equity (ROE)-0.14
Return on Assets (ROA)-0.13
Return on Invested Capital (ROIC)-16.77%
Return on Capital Employed (ROCE)-0.17
Revenue Per Employee0.00
Profits Per Employee-1.24M
Employee Count55
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.
PE Ratio―
PS Ratio0.00
PB Ratio1.40
Price to Fair Value5.95
Price to FCF-7.22
Price to Operating Cash Flow-7.22
PEG Ratio0.18
Income Statement
In the last 12 months, Bicara Therapeutics Inc. had revenue of 0.00 and earned -68.00M in profits. Earnings per share was -1.25.
Revenue0.00
Gross Profit0.00
Operating Income-82.39M
Pretax Income-67.81M
Net Income-68.00M
EBITDA-67.75M
Earnings Per Share (EPS)-1.25
Cash Flow
In the last 12 months, operating cash flow was -13.53M and capital expenditures 0.00, giving a free cash flow of -13.53M billion.
Operating Cash Flow-13.53M
Free Cash Flow-13.53M
Free Cash Flow per Share-0.25
Dividends & Yields
Bicara Therapeutics Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.70
52-Week Price Change-58.56%
50-Day Moving Average10.63
200-Day Moving Average14.59
Relative Strength Index (RSI)52.38
Average Volume (3m)515.10K
Important Dates
Bicara Therapeutics Inc. upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Bicara Therapeutics Inc. as a current ratio of 27.93, with Debt / Equity ratio of 0.13%
Current Ratio27.93
Quick Ratio27.93
Debt to Market Cap<0.01
Net Debt to EBITDA7.22
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Bicara Therapeutics Inc. has paid 187.00K in taxes.
Income Tax187.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Bicara Therapeutics Inc. EV to EBITDA ratio is -35.99, with an EV/FCF ratio of -32.59.
EV to Sales0.00
EV to EBITDA-35.99
EV to Free Cash Flow-32.59
EV to Operating Cash Flow-32.62
Balance Sheet
Bicara Therapeutics Inc. has $462.06M in cash and marketable securities with $591.00K in debt, giving a net cash position of -$461.47M billion.
Cash & Marketable Securities$462.06M
Total Debt$591.00K
Net Cash-$461.47M
Net Cash Per Share-$8.46
Tangible Book Value Per Share$2.93
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Bicara Therapeutics Inc. is $32.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$32.60
Price Target Upside193.43% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast―